DELAY IN KB5359 DEVELOPMENT

As one of its lead projects, Karo Bio develops selective thyroid hormone receptor agonists for the treatment of dyslipidemia. A successful phase II study with the most advanced compound, KB2115 was recently reported. Further development of KB2115, has the highest priority inside the company with additional phase II studies being initiated this year.

The second generation compound, KB5359, has generated some findings during toxicity testing that requires further evaluation. Hence, additional studies are needed and it is anticipated that the commencement of clinical trials will be delayed by approximately six months.

“It is unfortunate that we will have a delay in the development of KB5359 but we are addressing the issues with priority”, says Per Olof Wallström, CEO of Karo Bio. “The program is otherwise making good progress and we pursue the development of pharmacologically selective thyroid hormone receptor agonists with confidence”.

KARO BIO AB

For further information, please contact:
Per Olof Wallström, President & Chief Executive Officer
Telephone: +46 8 608 60 20

Per Otteskog, Senior Vice President
Telephone: +46 8 608 60 18